Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($0.24) for the year, down from their previous estimate of $1.88. Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Several other analysts also recently weighed in on ZVRA. Canaccord Genuity Group lifted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Guggenheim lifted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $22.29.

Remove Ads

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock traded down $0.38 during mid-day trading on Friday, hitting $7.97. 319,016 shares of the company's stock traded hands, compared to its average volume of 574,467. The firm has a 50 day moving average price of $7.92 and a 200 day moving average price of $8.17. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $431.30 million, a PE ratio of -4.05 and a beta of 1.98. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

Insider Transactions at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock valued at $674,176. Corporate insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently modified their holdings of ZVRA. Adage Capital Partners GP L.L.C. grew its holdings in shares of Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the last quarter. FMR LLC grew its holdings in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company's stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the last quarter. AIGH Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the fourth quarter valued at $6,577,000. Stonepine Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the third quarter valued at $4,858,000. Finally, Vestal Point Capital LP purchased a new position in shares of Zevra Therapeutics during the third quarter valued at $3,644,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.